United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Court Grants Endologix's Motion to Stay Patent Litigation
IRVINE, Calif., Jan 13, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that the United States Patent and Trademark Office (USPTO) has granted both of Endologix's requests for reexamination
View HTML
Toggle Summary CRYOLIFE AND ENDOLOGIX SIGN DEVELOPMENT AGREEMENT FOR BIOFOAM
Endologix to develop CryoLife’s innovative, self-expanding sealant as a filling agent for aortic aneurysms
View HTML
Toggle Summary Endologix Achieves Revenue Milestone for the Nellix(R) EndoVascular Aneurysm Sealing System
Triggers Endologix Common Stock Milestone Payment to Former Nellix Stockholders
View HTML
Toggle Summary Endologix Acknowledges Receipt of Unsolicited Offer from Elliot Associates
IRVINE, Calif., Oct 15, 2008 (BUSINESS WIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer of the Powerlink(R) System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today acknowledged receipt of an unsolicited proposal from Elliott Associates, L.P.
View HTML
Toggle Summary Endologix Added to Russell Indexes
IRVINE, Calif., June 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced that it has been added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes, effective June
View HTML
Toggle Summary Endologix AFX(R) Endovascular AAA System Receives Shonin Approval for Marketing in Japan
Announces Japan Lifeline as New Distribution Partner in Japan
View HTML
Toggle Summary Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products
Accelerates Endologix's Transition to Direct Sales in EuropeSupports LeMaitre's Strategy to Focus on Core Vascular Products
View HTML
Toggle Summary Endologix Announces $16.3 Million Private Placement
Endologix Announces $16.3 Million Private Placement Irvine, Calif. – March 8, 2004 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that it has signed definitive agreements to
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES $16.6 MILLION PRIVATE PLACEMENT
ENDOLOGIX ANNOUNCES $16.6 MILLION PRIVATE PLACEMENT Irvine, Calif. – July 6, 2005 – Endologix, Inc. (Nasdaq: ELGX), the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that it has signed definitive
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES $20.0 MILLION DIRECT EQUITY PLACEMENT
ENDOLOGIX ANNOUNCES $20.0 MILLION DIRECT EQUITY PLACEMENT IRVINE, Calif. (June 1, 2006) – Endologix, Inc. (Nasdaq: ELGX) today announced that it has entered into definitive agreements with several institutional investors for the sale of approximately 6.1 million shares of its common stock at
View HTML